Skip to main content

Improve the functional correlation of TCR T cells by replacing affinity with avidity

Part of: TCR T cells

Improve the functional correlation of TCR T cells by replacing affinity with avidity

Improve the functional correlation of TCR T
cells by replacing affinity with avidity

This study aimed to screen a panel of affinity-tuned TCR T cells and find the most potent candidates.

T cells with high antigen-affinity TCRs are, in general, functionally superior to those with low antigen-affinity. However, upon breaching an optimum, T-cell functionality diminishes, and negative T-cell regulation increases. The researchers selected three TCR constructs based on their affinity to evaluate T-cell avidities upon interaction with a melanoma cell line (Figure 1).

NY-ESO-1 peptide pulsing on QMα and DMβ resulted in marked avidity enhancement compared with the non-pulsed conditions  (Figure 2).  In contrast to affinity measurements, the avidity data correlated with T-cell function, explaining the diminishing results observed among T cells with the highest affinities.

The reverse relationship between affinities and avidities of QMα and DMβ can explain reduced functionalities of high-affinity TCR T cells. This outcome suggests that avidity is a better predictor of TCR T-cell functionality compared with affinity.

1 Panel of TCR-transduced T cells based on their affinity. WT (baseline), DMβ (medium affinity), and QMα (high affinity) were selected for the experiment.

2 Avidity curves showing the proportion of bound TCR T cells to non-pulsed or peptide-pulsed Na8 melanoma cells at increasing acoustic forces. Each plot represents measurements performed on WT (left), DMβ (center), or QMα (right). (rForce indicates relative force.)

Data courtesy of Dr. Nathalie Rufer at the University of Lausanne
Read more:
Hebeisen et al. (2013) Front. Immunol.

Our solutions

Cell avidity as a service

Cell Avidity analysis can be performed at high throughput using our services platform, enabling the screening of hundreds of Cell Engagers to rapidly find the most potent Cell Engager for in vivo testing. 

Dr. Rogier Reijmers
Principal Scientist at LUMICKS

Download the brochure to learn more

Join our mailing list

I would like to receive exclusive news about the latest product developments, dynamic single-molecule and immuno-oncology events and breakthrough science. I can revoke my consent at any time.

By submitting the form you agree to LUMICKS' privacy policy.

Close Menu

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us


Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck